These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 31680013)
1. US Food and Drug Administration approval of esketamine and brexanolone. Cristea IA; Naudet F Lancet Psychiatry; 2019 Dec; 6(12):975-977. PubMed ID: 31680013 [No Abstract] [Full Text] [Related]
2. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression. Powell JG; Garland S; Preston K; Piszczatoski C Ann Pharmacother; 2020 Feb; 54(2):157-163. PubMed ID: 31476884 [No Abstract] [Full Text] [Related]
7. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Kanes S; Colquhoun H; Gunduz-Bruce H; Raines S; Arnold R; Schacterle A; Doherty J; Epperson CN; Deligiannidis KM; Riesenberg R; Hoffmann E; Rubinow D; Jonas J; Paul S; Meltzer-Brody S Lancet; 2017 Jul; 390(10093):480-489. PubMed ID: 28619476 [TBL] [Abstract][Full Text] [Related]
8. Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care. Jarman AF; MacLean JV; Barron RJ; Wightman RS; McGregor AJ Clin Ther; 2020 Jan; 42(1):231-235. PubMed ID: 31910998 [TBL] [Abstract][Full Text] [Related]
9. Maternal and Newborn Safety During the Administration of Brexanolone: AWHONN Practice Brief Number 10. Association of Women’s Health, Obstetric and Neonatal Nurses J Obstet Gynecol Neonatal Nurs; 2020 Nov; 49(6):620-621. PubMed ID: 33069498 [No Abstract] [Full Text] [Related]
10. Brexanolone for the treatment of patients with postpartum depression. Morrison KE; Cole AB; Thompson SM; Bale TL Drugs Today (Barc); 2019 Sep; 55(9):537-544. PubMed ID: 31584571 [TBL] [Abstract][Full Text] [Related]
11. Brexanolone: First Global Approval. Scott LJ Drugs; 2019 May; 79(7):779-783. PubMed ID: 31006078 [TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development. Frieder A; Fersh M; Hainline R; Deligiannidis KM CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145 [TBL] [Abstract][Full Text] [Related]
13. Implementation of a Hospital-based Brexanolone Program. Howard MM; Diaz Z; Battle CL J Psychiatr Pract; 2022 Sep; 28(5):404-408. PubMed ID: 36074110 [TBL] [Abstract][Full Text] [Related]
14. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression. Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388 [No Abstract] [Full Text] [Related]
15. Brexanolone and postpartum depression: what does it have to do with GABA? Naguy A Arch Womens Ment Health; 2019 Dec; 22(6):833-834. PubMed ID: 31302763 [No Abstract] [Full Text] [Related]
16. Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies. Zheng W; Cai DB; Zheng W; Sim K; Ungvari GS; Peng XJ; Ning YP; Wang G; Xiang YT Psychiatry Res; 2019 Sep; 279():83-89. PubMed ID: 31323375 [TBL] [Abstract][Full Text] [Related]
17. Approval of esketamine for treatment-resistant depression. Singh JB; Daly EJ; Mathews M; Fedgchin M; Popova V; Hough D; Drevets WC Lancet Psychiatry; 2020 Mar; 7(3):232-235. PubMed ID: 32087801 [No Abstract] [Full Text] [Related]
18. Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience. Lüscher B; Möhler H F1000Res; 2019; 8():. PubMed ID: 31275559 [TBL] [Abstract][Full Text] [Related]
19. Esketamine for treatment resistant depression: a trick of smoke and mirrors? Gastaldon C; Papola D; Ostuzzi G; Barbui C Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104 [TBL] [Abstract][Full Text] [Related]
20. Brexanolone Is the First Drug Specifically for Postpartum Depression. Fantasia HC Nurs Womens Health; 2019 Oct; 23(5):450-454. PubMed ID: 31445988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]